The Overdose Prevention Engagement Network (OPEN) at the University of Michigan is a multidisciplinary team committed to improving lives and reducing harms of substance use. Through partnership with individuals, communities, and organizations, OPEN provides education and resources to strengthen person-centered prevention, treatment, and recovery efforts. OPEN has graciously extended a warm invitation to Indian Country providers to participate in their virtual trainings and webinar series throughout 2026 (and beyond). These sessions offer timely, clinically relevant content that can be applied across care settings, with CE credits available.
This informative webinar will examine the relative benefits and risks of kratom-derived products. This session will provide an overview of natural leaf kratom, mitragynine extracts, and isolated synthetic compounds (7-OH, mitragynine pseudoindoxyl, MGM-15/16), compare their pharmacologic profiles with traditional opioids, review available clinical and anecdotal data on potential risks and benefits, and discuss regulatory strategies aimed at reducing public health harms while preserving access to natural leaf kratom.
Learning Objectives:
- Describe the three different types of kratom derived products (natural leaf, mitragynine extracts, and isolated synthetics (7-OH, mitragynine pseudoindoxyl, MGM-15/16)
- Compare and contrast the pharmacologic similarities and differences between kratom derived products and with traditional opioids
- Describe the clinical trial and descriptive (anecdotal) data on kratom derived products to determine the potential risks and benefits
- Describe a regulatory approach to reduce public health risk but maintain access to natural leaf kratom
Presenter(s):
- Dr. C. Michael White, Pharm.D., FCP, FCCP, FASHP
1 CE Credit (1.0 hour):
- CME pending
- MCBAP
- Social Work
- Meets DEA Training Requirements